TB-CHAMP Trial Reveals key risk factors for TB Infection in children under five years of age.Young children have a high risk ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

A new review has examined how bipolar disorder medications interact with the gut microbiome, revealing important links ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

There would be no risk of XDR-TB infection ... Extensive drug resistance in TB is not a new phenomenon. It is created when multidrug-resistant TB (MDR-TB) patients are treated with second-line ...

Citation tracking, manual reference and ahead of press searches. Eligibility criteria for selecting studies Studies presenting prospective data evaluating factors associated with the risk of index and ...

In most cases, the cause of Parkinson’s disease remains unknown. But researchers have identified multiple risk factors that can increase your chances of getting this disease. Since most causes ...

in female patients between 18-65 years of age who have UTIs caused by multi-drug resistant E coli and have a history of prior UTIs caused by the organism. The BARDA funding will be used to LBP ...